Integrated Care Endorsed for CRPC

Share this article:
Integrated Care Endorsed for Castration-Resistant Prostate CA
Integrated Care Endorsed for Castration-Resistant Prostate CA

For patients with castration-resistant prostate cancer (CRPC), a therapeutic framework should involve an integrated approach, with joint management by a urologist and medical oncologist, researchers reported online ahead of print in Urologic Oncology.

Noting that the therapeutic landscape in CRPC has evolved rapidly in recent years, with five new systemic agents available, Ralph de Vere White, MD, and Primo N. Lara Jr., MD, from the University of California Davis Comprehensive Cancer Center in Sacramento, propose a framework for urology and medical oncology interaction to optimize treatment.

The authors note that all caregivers should be involved in an integrated and comprehensive approach, which requires joint management of CRPC by a urologist and a medical oncologist, from initial manifestations of castration resistance to the end of life. This partnership should involve the establishment of common management guidelines, which identify available therapeutic options and define treatment goals and responsibilities of each provider. The partnership could be used to develop and pursue clinical studies that would allow testing of different models of integrated patient management. Potential barriers to integrated care include financial considerations as well as logistical and regulatory barriers.

"The patient with CRPC deserves no better than an integrated care team that includes both urologic and medical oncology specialties, rather than being managed by a temporal sequence of specialists separated in time and space," the authors wrote.

Share this article:
You must be a registered member of RUN to post a comment.

More in Prostate Cancer

Prostate Brachytherapy On the Decline

Prostate Brachytherapy On the Decline

Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.

Osteoporosis May Be Present Before Prostate Cancer ADT

Osteoporosis May Be Present Before Prostate Cancer ADT

Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.